Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEAD1 | P28347 | 14/20 | 0.63 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.52 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.49 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | MMP13 | P45452 | 1/20 | 0.48 |
| ▸ | NAAA | Q02083 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27398364 | 1.00 | TEAD1 (0.63) | TEAD1LIPGCARM1PRMT6MMP2 | |
| SCHEMBL27399262 | 0.93 | TEAD1 (0.65) | TEAD1LIPGCARM1PRMT6MMP2 | |
| SCHEMBL27400014 | 0.90 | LIPG (0.52) | TEAD1LIPGCARM1PRMT6MMP2 | |
| SCHEMBL27398290 | 0.90 | LIPG (0.52) | TEAD1LIPGCARM1PRMT6MMP2 | |
| SCHEMBL27398844 | 0.88 | TEAD1 (0.60) | TEAD1LIPGEGFR | |
| SCHEMBL27398968 | 0.88 | TEAD1 (0.60) | TEAD1LIPGEGFR | |
| SCHEMBL27399385 | 0.87 | LIPG (0.49) | TEAD1LIPGCARM1PRMT6MMP2 | |
| SCHEMBL27398302 | 0.87 | LIPG (0.49) | TEAD1LIPGCARM1PRMT6MMP2 | |
| SCHEMBL27399389 | 0.87 | LIPG (0.49) | TEAD1LIPGCARM1PRMT6MMP2 | |
| SCHEMBL27398796 | 0.87 | LIPG (0.49) | TEAD1LIPGCARM1PRMT6MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024091511-A1 | HETEROCYCLIC TEAD INHIBITORS | LIGHT HORSE THERAPEUTICS, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2020081572-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | TEAD1, TEAD4, TEAD2 | TEAD1 1/4885LIPG 3706/4885CARM1 1732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.